## Aster DM Healthcare Limited (ASTERDM) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Aster DM Healthcare Limited (ASTERDM) is a leading healthcare provider operating primarily in the Middle East and India.  The company is listed on the National Stock Exchange of India (NSE) with the symbol ASTERDM, and its listing date is February 26, 2018.  ASTERDM operates hospitals, clinics, and pharmacies, and holds a significant position within the healthcare sector in its regions of operation.


**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹485.60         |                                                                      |
| Percentage Change (PChange) | -1.27%          | Negative change compared to the previous closing price.              |
| Pre-Open Activity          | ₹494.45 (Open)  |  Opened higher than the previous close, but the price has since decreased.  |
| Week High                   | ₹558            | High reached during the week.                                      |
| Week Low                    | ₹311.1          | Low reached during the week, indicating significant price volatility. |
| VWAP                        | ₹498.22         | Volume Weighted Average Price for the day.                           |
| Sector PE                   | 54.07           | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 54.07           | Price-to-Earnings ratio for ASTERDM.                               |
| Delivery Percentage         | 35.26%          | Relatively low delivery percentage suggests a significant portion of trading was speculative. |
| Market Depth                | Low              |  Based on the provided order book data, market depth appears low, indicating potential for price swings. |


**3. Financial Performance:**

The following table summarizes the financial performance of ASTERDM over the past five quarters.  Note that some figures show significant discrepancies, requiring further investigation into the source data's accuracy and consistency.  The provided data includes both audited and unaudited figures, which should be considered when interpreting the trends.

| Quarter      | Revenue (₹) | Expenses (₹) | Profit After Tax (₹) | EPS (₹) |
|--------------|-------------|-------------|-----------------------|---------|
| Q1 2024 (Jan-Mar) | 54,928      | 50,263      | -811                  | -0.16    |
| Q2 2024 (Apr-Jun) | 618,513     | 52,034      | 600,824                | 120.67  |
| Q3 2024 (Jul-Sep) | 65,142      | 53,159      | 8,984                 | 1.8     |
| Q4 2023 (Oct-Dec) | 53,783      | 48,464      | 5,319                 | 1.07    |
| Q3 2023 (Jul-Sep) | 52,969      | 47,300      | 5,906                 | 1.19    |


**Key Financial Ratio Observations:**  The significant jump in Q2 2024 revenue and profit is highly unusual and needs further investigation to determine its validity and underlying causes.  The other quarters show relatively consistent, though modest, profitability.


**4. Corporate Actions and Announcements:**

* **Dividends:**  ASTERDM declared an annual dividend of ₹2 per share (ex-date August 22, 2024) and a special dividend of ₹118 per share (ex-date April 23, 2024).  These are positive signals for investors.
* **Buyback:** A buyback occurred in January 2020.
* **Announcements:** Recent announcements include updates on acquisitions, analyst meetings, and credit rating revisions.  These require further analysis to assess their impact on the stock price.


**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 41.88                        | 57.70      | 0.41                           | 100.00    |
| 31-Dec-2023  | 41.88                        | 57.75      | 0.37                           | 100.00    |
| 31-Mar-2024  | 41.88                        | 57.77      | 0.35                           | 100.00    |
| 30-Jun-2024  | 41.88                        | 57.80      | 0.32                           | 100.00    |
| 30-Sep-2024  | 41.88                        | 57.82      | 0.30                           | 100.00    |

Promoter shareholding remains stable, while public shareholding shows a slight upward trend.  The decrease in employee trust shareholding is minimal and not a significant concern.


**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The CM Annual Volatility of 43.56% further confirms this.  The low market depth adds to the risk, as large trades could easily move the price.  The risk-reward profile is currently skewed towards higher risk due to volatility and the inconsistencies in the financial data.


**7. Advantages of Buying the Stock:**

* Consistent (excluding Q2 2024 anomaly) profitability.
* Strong promoter holding.
* Dividend payouts.
* Position in a growing healthcare sector.


**8. Disadvantages and Risks:**

* High volatility.
* Inconsistent financial reporting (requires further investigation).
* Low market depth.
* Dependence on the healthcare sector's performance and regulatory changes.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The current price volatility and inconsistencies in the financial data make a buy recommendation risky in the short term.  Holding allows for monitoring of the situation and potential short-term trading opportunities based on price movements.

* **Medium-term (3 to 12 months): Don't Buy.**  Until the inconsistencies in the financial data are clarified and the volatility subsides, a buy recommendation is not justified.  Further investigation into Q2 2024 results is crucial.

* **Long-term (1 year and beyond): Hold (if you have stock).**  The long-term prospects of ASTERDM are tied to the growth of the healthcare sector.  However, given the current uncertainties, a new investment is not recommended until more clarity emerges.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.0**

* Financial Health: 6/10 (Inconsistencies in data lower the score; otherwise, it would be higher.)
* Market Performance: 5/10 (High volatility and low market depth are significant drawbacks.)
* Volatility and Risk: 4/10 (High volatility and low market depth present considerable risk.)
* Corporate Actions & Governance: 8/10 (Dividend payouts and stable promoter holding are positive.)
* Shareholding Patterns: 7/10 (Stable promoter holding and slight increase in public holding are positive.)

**Analysis Score (out of 10): 8.0**

* Completeness and Data Utilization: 9/10 (Most data points were used effectively.)
* Accuracy and Clarity: 7/10 (Clarity is good, but accuracy is hampered by data inconsistencies.)
* Professional Formatting: 9/10 (Report is well-structured and easy to read.)


**11. Professional Recommendation Summary:**

ASTERDM presents a mixed picture.  While the company operates in a growing sector and has a history of dividend payouts, the significant inconsistencies in the recent financial data and high volatility create considerable uncertainty.  Therefore, a cautious approach is recommended.  Further investigation into the Q2 2024 financial results is crucial before making any investment decisions.  Until the inconsistencies are resolved and volatility decreases, a "Hold" recommendation is appropriate for existing investors, while a "Don't Buy" is recommended for potential new investors.  The situation should be closely monitored for future investment opportunities.
